We are live on ! Find out more
CABA icon

Cabaletta Bio

75 hedge funds and large institutions have $162M invested in Cabaletta Bio in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 31 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,676% more call options, than puts

Call options by funds: $5.26M | Put options by funds: $91K

46% more capital invested

Capital invested by funds: $111M → $162M (+$51.3M)

13% less funds holding

Funds holding: 8675 (-11)

23% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 31

52% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 21

67.73% less ownership

Funds ownership: 143.4%75.67% (-68%)

Holders
75
Holders Change
-11
Holders Change %
-12.79%
% of All Funds
0.98%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
24
Reduced
31
Closed
21
Calls
$5.26M
Puts
$91K
Net Calls
+$5.17M
Net Calls Change
+$3.51M
Name Holding Trade Value Shares
Change
Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$22.6M
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$20.7M
Jennison Associates
3
Jennison Associates
New York
$19.9M +$4.25M +2,477,370 +41%
T. Rowe Price Investment Management
4
T. Rowe Price Investment Management
Maryland
$19.6M +$2.69M +1,568,701 +23%
CAM
5
Cormorant Asset Management
Massachusetts
$11.7M
Vanguard Group
6
Vanguard Group
Pennsylvania
$9.81M +$1.27M +740,032 +21%
WP
7
Woodline Partners
California
$5M +$1.57M +916,884 +75%
HCM
8
Heights Capital Management
California
$4.88M -$1.82M -1,059,904 -34%
BlackRock
9
BlackRock
New York
$3.79M +$1.12M +650,271 +67%
SCM
10
Superstring Capital Management
New York
$3.61M +$830K +483,761 +46%
Morgan Stanley
11
Morgan Stanley
New York
$3.45M +$257K +149,870 +11%
Renaissance Technologies
12
Renaissance Technologies
New York
$3.13M +$2.08M +1,213,323 +962%
Marshall Wace
13
Marshall Wace
United Kingdom
$3.1M +$1.95M +1,135,086 +594%
Alyeska Investment Group
14
Alyeska Investment Group
Illinois
$3.04M -$6.01M -3,500,000 -73%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$3.03M -$1.53M -892,090 -41%
SSA
16
Schonfeld Strategic Advisors
New York
$2.44M -$756K -440,667 -30%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$2.15M +$629K +366,878 +66%
OM
18
Opaleye Management
Massachusetts
$1.89M +$1.39M +808,882 New
Citadel Advisors
19
Citadel Advisors
Florida
$1.65M -$1.69M -982,515 -58%
BGM
20
Burkehill Global Management
New York
$1.64M -$2.06M -1,200,000 -63%
Millennium Management
21
Millennium Management
New York
$1.61M -$289K -168,517 -20%
JP Morgan Chase
22
JP Morgan Chase
New York
$1.26M +$784K +456,853 +565%
Two Sigma Investments
23
Two Sigma Investments
New York
$1.1M +$374K +218,118 +86%
UBS Group
24
UBS Group
Switzerland
$948K -$115K -66,922 -14%
AC
25
Almitas Capital
California
$907K +$34.3K +20,000 +5%

CABA Hedge Fund Activity: Q3 2025 in Review

75 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q3 2025, worth a combined $162M — up 46% from $111M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of CABA and 10 opened new positions — a net loss of 11 holders — while 31 trimmed existing stakes and 24 added.

The largest buyer was Jennison Associates, adding an estimated $4.25M. The largest seller was Alyeska Investment Group, cutting an estimated $6.01M.

  • 75 institutional investors held Cabaletta Bio (CABA) as of Q3 2025, down from 86 in Q2 2025.
  • Funds reported $162M of Cabaletta Bio stock for Q3 2025, up 46% quarter-over-quarter.
  • 10 funds opened new Cabaletta Bio positions in Q3 2025 and 21 closed out, a net change of -11 holders.
  • The largest Cabaletta Bio buyer in Q3 2025 was Jennison Associates, an estimated $4.25M added.
  • The largest Cabaletta Bio seller in Q3 2025 was Alyeska Investment Group, an estimated $6.01M sold.

Based on aggregated 13F filings for Q3 2025.